Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
GDTC Stock Forecast 2026-2027
$1.02
Current Price
$12.07M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to GDTC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
GDTC Price Momentum
+2.0%
1 Week Change
-7.3%
1 Month Change
-56.2%
1 Year Change
-23.9%
Year-to-Date Change
-72.3%
From 52W High of $3.68
+40.1%
From 52W Low of $0.73
๐ TOP ANALYST CALLS
Did GDTC Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if CytoMed is one of their latest high-conviction picks.
Latest GDTC Stock Price Targets & Analyst Predictions
GDTC has shown a year-to-date change of -23.9% and a 1-year change of -56.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for GDTC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GDTC Analyst Ratings
1
Buy
0
Hold
0
Sell
GDTC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.02
Latest GDTC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GDTC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 10, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $5.00 |
| Jun 11, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $5.00 |
| Dec 4, 2023 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $5.00 |
| Jul 21, 2023 | Benchmark | Bruce Jackson | Speculative Buy | Initiates | $5.00 |
Cytomed Therapeutics Ltd. (GDTC) Competitors
The following stocks are similar to CytoMed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cytomed Therapeutics Ltd. (GDTC) Financial Data
Valuation Metrics
Market Cap
$12.07M
Enterprise Value
$8.38M
P/E Ratio
N/A
PEG Ratio
-6.7x
Price/Sales
13.7x
Growth & Margins
Revenue Growth (YoY)
+46.9%
Gross Margin
N/A
Operating Margin
-535.3%
Net Margin
+79.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+17.4%
Current Ratio
5.2x
Debt/Equity
7.0x
ROE
-50.3%
ROA
-29.3%
๐ก SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Cytomed Therapeutics Ltd. (GDTC) Business Model
About Cytomed Therapeutics Ltd.
What They Do
Develops innovative medical therapies for rare diseases.
Business Model
Cytomed Therapeutics Ltd. focuses on research, development, and commercialization of novel treatments, particularly for rare diseases and complex conditions. The company generates revenue through collaborative partnerships and advancing its drug development pipeline to market effective therapies.
Additional Information
Cytomed is positioned as a key player in the biotechnology sector, attracting investor interest due to its potential for groundbreaking advancements. Progress in clinical trials and securing regulatory approvals will be critical for its market position and investor confidence.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
43
CEO
Dr. Wee Kiat Tan Ph.D.
Country
Singapore
IPO Year
2023
Website
w2.cytomed.sgCytomed Therapeutics Ltd. (GDTC) Latest News & Analysis
Latest News
Quick Summary
CytoMed Therapeutics (NASDAQ: GDTC) will hold its Q2 2025 earnings call on October 2, 2025, at 10:00 AM EDT, featuring CFO Yvonne Goh.
Why It Matters
The earnings call indicates upcoming financial performance insights for CytoMed Therapeutics, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
CytoMed Therapeutics (NASDAQ: GDTC) announced promising preclinical results for its ฮณฮด T cell therapy targeting acute myeloid leukemia, in collaboration with MD Anderson Cancer Center.
Why It Matters
CytoMed's preclinical study shows potential for its ฮณฮด T cell therapy in treating AML, signaling advancements in immunotherapy and possible market opportunities, impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CytoMed Therapeutics has successfully expanded clinical-scale NK cells from decade-old cord blood, positioning itself to create new revenue streams and enhance future growth potential.
Why It Matters
CytoMed's breakthrough in expanding NK cells from long-stored cord blood enhances its immunotherapy portfolio, potentially driving revenue growth and attracting investor interest in innovative cancer treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CytoMed Therapeutics (NASDAQ: GDTC) has signed an At-the-Market Sales Agreement with R.F. Lafferty & Co. to facilitate the sale of its shares, focusing on cell-based cancer therapies.
Why It Matters
CytoMed's At-the-Market Sales Agreement allows for flexible capital raising, potentially enhancing liquidity and funding for its cancer therapies, impacting growth prospects and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CytoMed Therapeutics (NASDAQ: GDTC) has successfully completed dose level 1 of its Phase I ANGELICA Trial for cancer treatments and will start dose level 2 in Q3 2025.
Why It Matters
Successful trial progress for CytoMed could signal potential breakthroughs in cancer treatment, impacting stock performance and investor sentiment in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Resultsย and Provides Clinical and Corporate Updates
11 months ago
Quick Summary
CytoMed Therapeutics Limited (NASDAQ: GDTC) reported its 2024 financial results and shared clinical updates, focusing on affordable allogeneic immunotherapies without external manufacturing or research.
Why It Matters
CytoMed's focus on affordable allogeneic immunotherapies and its financial results could influence investor confidence and stock performance in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GDTC Stock
What is Cytomed Therapeutics Ltd.'s (GDTC) stock forecast for 2026?
Analyst forecasts for Cytomed Therapeutics Ltd. (GDTC) are not currently available. The stock is trading at $1.02.
Is GDTC stock a good investment in 2026?
According to current analyst ratings, GDTC has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GDTC stock?
Price predictions from Wall Street analysts for GDTC are not currently available. The stock is trading at $1.02.
What is Cytomed Therapeutics Ltd.'s business model?
Cytomed Therapeutics Ltd. focuses on research, development, and commercialization of novel treatments, particularly for rare diseases and complex conditions. The company generates revenue through collaborative partnerships and advancing its drug development pipeline to market effective therapies.
What is the highest forecasted price for GDTC Cytomed Therapeutics Ltd.?
Price targets from Wall Street analysts for GDTC are not currently available. The stock is trading at $1.02.
What is the lowest forecasted price for GDTC Cytomed Therapeutics Ltd.?
Price targets from Wall Street analysts for GDTC are not currently available. The stock is trading at $1.02.
What is the overall GDTC consensus from analysts for Cytomed Therapeutics Ltd.?
The overall analyst consensus for GDTC is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are GDTC stock price projections?
Stock price projections, including those for Cytomed Therapeutics Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 6:20 AM UTC